Revolution Medicines's competitors

Revolution Medicines's competitors include Shire, Chiasma, LGC Biosearch Technologies and Loxo Oncology
Add company...
Revolution Medicines
REVOLUTION Medicines is redesigning evolution's products to treat serious diseases. The company discovers and develops new drugs by deploying our innovative product engine to reconfigure substances that are inherently rich with biological function as a result of natural selection.
Shire
Shire PLC is a specialty biopharmaceutical company.
Chiasma
Chiasma is a biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for their rare and serious chronic diseases.
LGC Biosearch Technologies
LGC is an international leader in the laboratory services, measurement standards, reference materials, genomics and proficiency testing marketplaces.
Loxo Oncology
Loxo Oncology is a biopharmaceutical company focused on targeted cancer therapies for genetically-defined patient populations.
Founding Date
Founding Date
2015
Founding Date
1986
Founding Date
2001
Founding Date
1842
Founding Date
2013
Type
Type
Private
Type
Public
Type
Public
Type
Subsidiary
Type
Public
Tags
Locations
Locations
Redwood City, US HQ
Locations
Jersey, JE HQ
Buenos Aires, AR
Sydney, AU
Vienna, AT
Brussels, BE
São Paulo, BR
Sofia, BG
see more
Locations
Waltham, US HQ
Ness Ziona, IL
Locations
Teddington, GB HQ
Locations
Stamford, US HQ
South San Francisco, US
Employees
Employees
49 2% increase
Employees
23,906
Employees
17 26% decrease
Employees
901
Employees
47 57% increase
Valuation ($)
Valuation ($)
N/A
Valuation ($)
42.4 b
Valuation ($)
37.8 m
Valuation ($)
N/A
Valuation ($)
1.8 b
Twitter followers
Twitter followers
N/A
Twitter followers
5.8 k
Twitter followers
41
Twitter followers
2.3 k
Twitter followers
46

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
£47.6m (FY, 2016)
Revenue (est.)
N/A
Revenue (est.)
£108.1m (FY, 2017)
Revenue (est.)
N/A
Net income
Net income
N/A
Net income
£2.5m (FY, 2016)
Net income
($61.1m) (FY, 2016)
Net income
(£4.3m) (FY, 2017)
Net income
($72.4m) (FY, 2016)
For sources of this data, please see the company profileDownload Excel

View company profiles